CION Ameerpet
Classical Hodgkin lymphoma is the most common form of Hodgkin lymphoma and one of the most curable adult cancers. This guide explains its four subtypes and how CION's haematology team confirms, stages and treats it.
Classical Hodgkin lymphoma (cHL) is the most common form of Hodgkin lymphoma, making up roughly 9 in 10 cases. What defines it is a distinctive cell — the large, abnormal Reed-Sternberg cell — sitting in a background of normal immune cells. These tumour cells typically carry the CD30 marker (and often CD15), which pathologists confirm by immunostaining on the biopsy tissue. This marker is not just a label: it is one of the features that separates classical Hodgkin from other lymphomas, and it can also be a target for treatment.
Classical Hodgkin lymphoma usually begins in a group of lymph nodes — most often in the neck or chest — and tends to spread in an orderly way from one node group to the next. Because it responds so well to treatment, it is among the most curable of all adult cancers. The most useful things to understand early are your subtype and your stage: together they shape the plan and the outlook.
This page focuses on classical Hodgkin lymphoma and its subtypes. For a broader overview see the Lymphoma hub, and to plan care see Lymphoma Treatment in Hyderabad. If you want to meet the team, our best lymphoma doctors in Hyderabad and lymphoma hospital pages explain how CION works.
Classical Hodgkin lymphoma accounts for about 90 percent of all Hodgkin lymphoma cases, and the rest is nodular lymphocyte-predominant Hodgkin lymphoma — a separate disease. What ties all classical subtypes together is the Reed-Sternberg cell, which typically carries the CD30 marker on its surface. That single marker not only helps confirm the diagnosis under the microscope, it is also a therapeutic target used in selected cases. (Source: World Health Organization classification of lymphoid tumours, as referenced in NCCN and ESMO Hodgkin lymphoma guidelines.)
The most common first sign is a painless, firm swelling of a lymph node, typically in the neck, above the collarbone, or in the armpit. Some people also have so-called "B symptoms" — unexplained fevers, drenching night sweats, or unintentional weight loss — which are noted at diagnosis because they influence staging and the plan. Persistent tiredness, itching, or (uncommonly) discomfort after alcohol are also described.
These signs have many ordinary, non-cancer causes. But a lymph-node swelling that is painless, firm and does not settle over a few weeks should always be checked. For a detailed look at warning signs across the disease, see our Hodgkin lymphoma symptoms page. If you have a confirmed diagnosis, speak to a CION haematologist for a second opinion.
Getting the subtype and stage right — and then treating with a response-adapted plan — is what gives classical Hodgkin lymphoma its excellent outcomes. That is exactly how CION approaches it.
We favour an excisional (whole-node) biopsy so the pathologist can read both the cells and the architecture, and confirm Reed-Sternberg cells with CD30/CD15 immunostaining — the step that separates classical Hodgkin from a lymphocyte-predominant subtype.
Treatment is tailored to stage and to an interim PET-CT, so therapy can be escalated or de-escalated based on how well the lymphoma responds — the approach recommended by NCCN and ESMO.
CION delivers chemotherapy, antibody-based immunotherapy, precision radiation (IMRT) and monitoring directly. Where relapsed disease needs a stem-cell transplant, we coordinate it through an accredited partner facility.
Every case is reviewed by a multidisciplinary tumour board before the plan is set, and long-term survivorship care watches for the late effects that matter in a highly curable, often young-adult cancer.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just diagnosed with classical Hodgkin lymphoma, unsure what your subtype and stage mean, or want a second opinion before treatment? CION's haematology team is here.
The World Health Organization recognises four subtypes of classical Hodgkin lymphoma. They are distinguished by how the Reed-Sternberg cells and the surrounding tissue appear under the microscope. All four share the same core biology and are treated on the same principles — the subtype gives useful context, but stage and risk features drive the plan more than the subtype name alone.
| Subtype | How common | Typical picture |
|---|---|---|
| Nodular sclerosis | Most common | Often in adolescents & younger adults; frequently a chest (mediastinal) mass; fibrous bands on biopsy |
| Mixed cellularity | Second most common | More common in older adults; can present at a more advanced stage; mixed inflammatory background |
| Lymphocyte rich | Uncommon | Often older adults, early stage; many small lymphocytes around the tumour cells; favourable outlook |
| Lymphocyte depleted | Rarest | Least common; more Reed-Sternberg cells with fewer background lymphocytes |
Subtypes and outcomes vary by individual; this table is a general guide. Subtyping is decided by a pathologist on tissue with immunostaining, following the WHO classification and NCCN/ESMO guidance.
The most common subtype, especially in teenagers and younger adults, and it often presents as a mass in the chest. The biopsy shows characteristic bands of fibrous tissue. It generally responds very well to standard, stage-guided treatment. For more detail, see our dedicated nodular sclerosis Hodgkin lymphoma page.
The next most common subtype. Mixed cellularity Hodgkin is seen more often in older adults and can be diagnosed at a more advanced stage, with a mixed background of inflammatory cells surrounding the Reed-Sternberg cells. It is treated on the same core principles as the other subtypes, guided by stage and response.
An uncommon subtype in which many small, normal lymphocytes surround the tumour cells. Lymphocyte rich Hodgkin tends to occur in older adults, is often found at an early stage, and generally carries a favourable outlook. Pathologists take care to separate it from nodular lymphocyte-predominant Hodgkin lymphoma, which looks similar but is a different disease.
The rarest subtype, with relatively more Reed-Sternberg cells and fewer background lymphocytes. It is uncommon and, like the others, is managed with stage-guided, response-adapted treatment.
Confirming classical Hodgkin lymphoma — and pinning down its exact subtype and stage — follows a clear pathway. CION delivers the biopsy coordination, staging imaging and review directly, and discusses every case at a tumour board.
The diagnosis is made on a biopsy of an affected node. An excisional (whole-node) biopsy is preferred, because the pathologist needs to see the tissue architecture as well as the cells — a small needle sample alone is often not enough for Hodgkin lymphoma. The pathologist identifies Reed-Sternberg cells and confirms them with immunostaining for markers such as CD30 and CD15.
Once the diagnosis is confirmed, a PET-CT scan maps how far the lymphoma has spread and assigns a stage (I to IV). The stage, together with risk features such as bulky disease or B symptoms, is what most strongly shapes the treatment plan. Blood tests assess your general health, and a bone-marrow examination is done in selected cases.
All the pieces — biopsy, subtype, stage and your overall health — are brought together and reviewed by a multidisciplinary tumour board before any plan is finalised. This is the standard CION follows for every lymphoma case.
Classical Hodgkin lymphoma is one of the most treatable adult cancers, and the plan is built around your stage and how the disease responds to the first phase of treatment. Every case is reviewed by CION's tumour board before treatment starts. The main building blocks are described below by their role — for regimen names and drug-specific detail, please see our Lymphoma Treatment in Hyderabad page.
The backbone of treatment is a course of combination chemotherapy. Response is checked partway through with an interim PET-CT, allowing the team to escalate or de-escalate — a response-adapted approach endorsed by NCCN and ESMO. CION's medical oncology team delivers systemic therapy directly.
In many early-stage cases, a short course of precision radiation therapy is added to the involved sites after chemotherapy. CION delivers IMRT directly, shaping the beam to the affected nodes while sparing healthy tissue — an important consideration given how well most patients live long after treatment.
Because Reed-Sternberg cells typically carry the CD30 marker, antibody-based therapies that target CD30, and other immunotherapy approaches, are used in selected situations — for example in higher-risk or relapsed disease. These are delivered by CION's team as part of a coordinated plan.
Most people with classical Hodgkin lymphoma do very well, but if the disease comes back, effective options exist. Salvage systemic therapy is often followed by a stem-cell transplant, which CION coordinates through an accredited partner facility rather than delivering in-house. For a full discussion of relapse options, see our relapsed Hodgkin lymphoma page.
Classical Hodgkin lymphoma has one of the best outlooks of any adult cancer. Across published series, overall survival for Hodgkin lymphoma is commonly reported in the range of about 80 to 90 percent, with early-stage, favourable-risk disease doing best. For comparison, an aggressive non-Hodgkin lymphoma such as diffuse large B-cell lymphoma is typically reported around 60 to 70 percent (published series; figures vary by study and by individual). These are averages, not a prediction for any one person — your subtype, stage, age and response all matter. For detailed cure-rate context, see our Hodgkin lymphoma survival & cure rates page.
Two situations deserve special mention. Because classical Hodgkin lymphoma is common in young adults, protecting long-term health — fertility, heart and lung health, and second-cancer awareness — is built into the plan from the start. And when Hodgkin lymphoma is diagnosed during pregnancy, care is carefully coordinated between the haematology and obstetric teams to protect both mother and baby.
A classical Hodgkin lymphoma diagnosis carries important nuance, and a second opinion is especially worthwhile when:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if your subtype is uncertain or staging is not yet complete.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Classical Hodgkin lymphoma (cHL) is the most common form of Hodgkin lymphoma, accounting for roughly 9 in 10 cases. It is defined by the presence of large, abnormal cells called Reed-Sternberg cells, which typically carry the CD30 marker (and often CD15) on their surface — a feature pathologists confirm on the biopsy. Classical Hodgkin lymphoma is a distinct entity from nodular lymphocyte-predominant Hodgkin lymphoma, which behaves differently. It usually starts in lymph nodes of the neck or chest and tends to spread in an orderly way from one node group to the next. Because it is highly responsive to treatment, classical Hodgkin lymphoma is among the most curable cancers in adults. To plan care, see our Lymphoma Treatment in Hyderabad page.
The World Health Organization recognises four subtypes of classical Hodgkin lymphoma, distinguished under the microscope by how the Reed-Sternberg cells and the surrounding tissue look. Nodular sclerosis is the most common, especially in younger adults, and often presents with a mass in the chest — read more on our nodular sclerosis Hodgkin lymphoma page. Mixed cellularity Hodgkin is the next most frequent, more common in older adults and in advanced-stage disease. Lymphocyte-rich Hodgkin is uncommon and generally has a favourable outlook. Lymphocyte-depleted is the rarest and least common. All four are treated on the same core principles, though stage and risk features guide the exact plan.
Both are subtypes of classical Hodgkin lymphoma and share the same Reed-Sternberg cells, but they differ in who they affect and how the tissue appears. Nodular sclerosis Hodgkin lymphoma is the most common subtype, typically seen in adolescents and younger adults, and often involves lymph nodes in the chest with bands of fibrous (scar-like) tissue on the biopsy. Mixed cellularity Hodgkin is more common in older adults and can be associated with more advanced-stage disease at diagnosis; the biopsy shows a mixture of inflammatory cells around the tumour cells. Despite these differences, the subtype alone does not decide the treatment — the stage, symptoms and risk features matter more. Both subtypes respond well to standard, stage-guided therapy.
Lymphocyte rich Hodgkin lymphoma is one of the four subtypes of classical Hodgkin lymphoma and is relatively uncommon. Under the microscope, the tumour tissue contains many small, normal-looking lymphocytes surrounding the classical Reed-Sternberg cells, which still carry the CD30 marker. It is more often seen in older adults and usually presents at an early stage, without the bulky disease or B symptoms sometimes seen in other subtypes. Because of this, lymphocyte rich Hodgkin generally carries a favourable outlook. It is important to distinguish lymphocyte rich classical Hodgkin from nodular lymphocyte-predominant Hodgkin lymphoma, which looks superficially similar but is a separate disease with different biology and management — a distinction pathologists make using immunostaining.
The diagnosis of classical Hodgkin lymphoma is made on a biopsy of an affected lymph node — ideally an excisional (whole-node) biopsy, because the pathologist needs to see the architecture as well as the cells. A needle biopsy alone is often not enough. The pathologist looks for Reed-Sternberg cells and confirms them with immunostaining for markers such as CD30 and CD15. Once confirmed, staging scans — usually a PET-CT — map how far the lymphoma has spread, and blood tests assess your general health. A bone-marrow examination is sometimes done. All of this is reviewed together, and at CION every case is discussed by a multidisciplinary tumour board before a plan is set. Learn more on our Lymphoma Treatment page.
Classical Hodgkin lymphoma is treated based on its stage and risk features, and it is one of the most treatable adult cancers. The core approach combines multi-agent chemotherapy with, in many early-stage cases, a course of precision radiation therapy (IMRT) directed at the involved sites. Response is checked with an interim PET-CT so treatment can be tailored — a strategy endorsed by NCCN and ESMO guidelines. Antibody-based (immunotherapy) approaches, including agents that target the CD30 marker on Reed-Sternberg cells, are used in selected situations. CION delivers chemotherapy, immunotherapy, radiation and monitoring directly; where a stem-cell transplant is needed for relapsed disease, it is coordinated through an accredited partner facility. For drug-specific and regimen questions, please see our Lymphoma Treatment in Hyderabad page.
Classical Hodgkin lymphoma has one of the best outlooks of any adult cancer. Across published series, overall survival for Hodgkin lymphoma is commonly reported in the range of about 80 to 90 percent, with early-stage, favourable-risk disease doing better than advanced or bulky disease. By comparison, an aggressive non-Hodgkin lymphoma such as diffuse large B-cell lymphoma is typically reported around 60 to 70 percent (published series; figures vary by study and individual). These numbers are averages, not predictions for any one person — your subtype, stage, age and response to the first treatment all matter. Figures also vary by individual and by how early the lymphoma is found. For a picture built around your own reports, request a free second opinion from CION's lymphoma team.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.